Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance

Haematologica

Volumn 99, Issue 1, 2014, Pages 155-162

  Thiago, Leandro S ^a,c   Perez Andres, Martin ^a,c   Balanzategui, Ana ^b   Sarasquete, Maria E ^b   Paiva, Bruno ^b   Jara Acevedo, Maria ^a   Barcena, Paloma ^c   Luz Sanchez, Maria ^c   Almeida, Julia ^a,c   González, Marcos ^a,b   San Miguel, Jesus F ^a,b   Garcia Sanz, Ramón ^a,b   Orfao, Alberto ^a,c  

^a CSIC   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

B-LYMPHOCYTE SUBSETS; B-LYMPHOCYTES; CLONE CELLS; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; PLASMA CELLS; RECEPTORS, ANTIGEN, B-CELL;

EID: 84892570665     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.092817     Document Type: Article

References (39)

1. San Miguel JF, García-Sanz R, González M, Moro MJ, Hernández JM, Ortega F, et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood. 1995;85(2):448-55.
2. Bergsagel PL, Masellis Smith A, Belch AR, Pilarski LM. The blood B-cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangements. Curr Top Microbiol Immunol. 1995;194:17-24.
3. Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR, Pilarski LM. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-poly-merase chain reaction. Blood. 1998;92(8): 2844-55.
4. Pilarski LM, Hipperson G, Seeberger K, Pruski E, Coupland RW, Belch AR. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice. Blood. 2000;95(3):1056-65.
5. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103(6):2332-6.
6. Rasmussen T, Haaber J, Dahl IM, Knudsen LM, Kerndrup GB, Lodahl M, et al. Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma. Haematologica. 2010;95(10):1730-7.
7. Boucher K, Parquet N, Widen R, Shain K, Baz R, Alsina M, et al. Stemness of B-cell progenitors in multiple myeloma bone marrow. Clin Cancer Res. 2012;18(22): 6155-68.
8. Zojer N, Schuster-Kolbe J, Assmann I, Ackermann J, Strasser K, Hübl W, et al. Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance. Br J Haematol. 2002;117(4):852-9.
9. Sahota SS, Leo R, Hamblin TJ, Stevenson FK. Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. Blood. 1996;87 (2):746-55.
10. Schmidt-Hieber M, Gutiérrez ML, Pérez-Andrés M, Paiva B, Rasillo A, Tabernero MD, et al. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells. Haematologica. 2013;98(2):279-87.
11. Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012;120(5):1077-86.
12. Billadeau D, Van Ness B, Kimlinger T, Kyle RA, Therneau TM, Greipp PR, et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood. 1996; 88(1):289-96.
13. Schneider U, van Lessen A, Huhn D, Serke S. Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen. Br J Haematol. 1997;97(1): 56-64.
14. Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol. 1997;97(1):46-55.
15. Luque R, Brieva JA, Moreno A, Manzanal A, Escribano L, Villarrubia J, et al. Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients-diagnostic and clinical implications. Clin Exp Immunol. 1998;112 (3):410-8.
16. Paiva B, Pérez-Andrés M, Vídriales MB, Almeida J, de las Heras N, Mateos MV, et al. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia 2011;25(4):697-706.
17. Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley J F, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysio-logic and clinical implications. Blood. 2011;117(17):4409-19.
18. Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intra-clonal variation. Blood. 1992;80(9): 2326-35.
19. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68(1):190-7.
20. Paino T, Ocio EM, Paiva B, San-Segundo L, Garayoa M, Gutierrez NC, et al. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phe-notype. Haematologica. 2012;97(7):1110-4.
21. Kim D, Park CY, Medeiros BC, Weissman IL. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia. 2012;26(12): 2530-7.
22. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood. 1999;94(10): 3576-82.
23. Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia. 2004;18(11):1891-7.
24. Musto P, Carella AM Jr, Greco MM, Falcone A, Sanpaolo G, Bodenizza C, et al. Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. Br J Haematol. 2003(4);123:746-7.
25. Zojer N, Kirchbacher K, Vesely M, Hübl W, Ludwig H. Rituximab treatment provides no clinical benefit in patients with pretreat-ed advanced multiple myeloma. Leuk Lymphoma. 2006;47(6):1103-9.
26. Pfeifer S, Perez-Andres M, Ludwig H, Sahota SS, Zojer N. Evaluating the clonal hierarchy in light-chain multiple myeloma: implications against the myeloma stem cell hypothesis. Leukemia. 2011;25(7):1213-6.
27. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. B J Haematol. 2003;121(5):749-57.
28. Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Böttcher S, Ritgen M, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012;26(9):1986-2010.
29. Caraux A, Klein B, Paiva B, Bret C, Schmitz A, Fuhler GM, et al. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica 2010;95(6):1016-20.
30. Paiva B, Gutiérrez NC, Chen X, Vídriales MB, Montalbán MÁ, Rosiñol L, et al; Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia. 2012;26(8):1862-9.
31. Perez-Andres M, Paiva B, Nieto WG, Caraux A, Schmitz A, Almeida J, et al. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom. 2010;78 (Suppl 1):S47-60.
32. van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clon-al immunoglobulin and T-cell receptor gene recombinations in suspect lymphoprolifer-ations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-317.
33. Langerak AW, Groenen PJ, Bruggemann M, Beldjord K, Bellan C, Bonello L, et al. EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoprolif-erations. Leukemia. 2012;26(10):2159-71.
34. Puig N, Sarasquete ME, Alcoceba M, Balanzategui A, Chillon MC, Sebastian E, et al. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma. Ann.Hematol. 2013;92(1):97-100.
35. Sarasquete ME, García-Sanz R, González D, Martínez J, Mateo G, Martínez P, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005(10); 90:1365-72.
36. Mellstedt H, Hammarström S, Holm G. Monoclonal lymphocyte population in human plasma cell myeloma. Clin Exp Immunol. 1974(3);17:371-84.
37. Kubagawa H, Vogler LB, Capra JD, Conrad ME, Lawton AR, Cooper MD. Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation. J Exp Med. 1979(4);150:792-807.
38. Chen BJ, Epstein J. Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells. Blood. 1996;87(5): 1972-6.
39. Joshua DE, Brown RD, Luo XF, Gibson J. Circulating clonal lymphocytes in myeloma determined by mRNA in situ hybridization. Blood. 1996;88(3):1125.